Moderna Inc. (MRNA) shares rose by 7.3% in premarket trading following the announcement of stock purchases by the company's CEO and director. The stock continued to climb, reaching nearly a 10% increase during the day. This surge is attributed to insider buying, with reports indicating that the CEO and director purchased approximately $6 million worth of shares after previously selling $3.7 billion in stock. Additionally, Moderna is optimistic about a substantial revenue opportunity in cancer treatment, as it plans to launch a personalized cancer vaccine in collaboration with Merck (MRK) by 2027. This initiative reflects the company's ongoing commitment to expanding its portfolio beyond its COVID-19 vaccine offerings.